324800
Epoxomicin
≥95% (HPLC), solid, proteasome inhibitor, Calbiochem®
Synonyme(s) :
Epoxomicin, Synthetic, Proteasome Inhibitor XIV
Se connecter pour consulter les tarifs organisationnels et contractuels.
Sélectionner une taille de conditionnement
Changer de vue
A propos de cet article
Formule empirique (notation de Hill) :
C28H50N4O7
Poids moléculaire :
554.72
UNSPSC Code:
12352202
NACRES:
NA.77
Assay:
≥95% (HPLC)
Form:
solid
Quality level:
Storage condition:
OK to freeze, protect from light
Service technique
Besoin d'aide ? Notre équipe de scientifiques expérimentés est là pour vous.
Laissez-nous vous aiderNom du produit
Epoxomicin, Synthetic, Epoxomicin, Synthetic, CAS 134381-21-8, is a potent, specific, and irreversible inhibitor of chymotrypsin-like, trypsin-like, and peptidyl-glutamyl peptide hydrolyzing activities of the proteasome.
Quality Level
assay
≥95% (HPLC)
form
solid
manufacturer/tradename
Calbiochem®
storage condition
OK to freeze, protect from light
color
white
solubility
DMSO: 1 mg/mL, methanol: 1 mg/mL
shipped in
ambient
storage temp.
−20°C
General description
An antitumor agent of microbial origin that acts as a potent, highly specific, and irreversible inhibitor of chymotrypsin-like (CT-L), trypsin-like (T-L), and peptidylglutamyl peptide hydrolyzing (PGPH) activities of the proteasome. Modifies the proteasomal catalytic subunits LMP-7, MECL1, and Z. Epoxomicin also displays potent anti-inflammatory activity in vivo.
An antitumor and anti-inflammatory agent that acts as a potent, highly specific, and irreversible inhibitor of chymotrypsin-like (CT-L), trypsin-like (T-L), and peptidyl-glutamyl peptide hydrolyzing (PGPH) activities of the proteasome. Modifies the proteasomal catalytic subunits LMP-7, MECL1, and Z. Does not affect the activities of non-proteasomal proteases such as trypsin, cathepsin B, or chymotrypsin. A 1 mM (50 µg/90 µl) solution of Epoxomicin, Synthetic (Cat. No. 324801) in DMSO is also available.
Biochem/physiol Actions
Cell permeable: no
Primary Target
CT-L,T-L,PGPH activity of proteasome
CT-L,T-L,PGPH activity of proteasome
Product does not compete with ATP.
Reversible: no
Packaging
Packaged under inert gas
Preparation Note
Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 1 month at -20°C.
Other Notes
Meng, L., et al. 1999. Proc. Natl. Acad. Sci. USA 96, 10403.
Sin, N., et al. 1999. Bioorg. Med. Chem. Lett. 9, 2283.
Hanada, M., et al. 1992. J. Antibiot. 45, 1746.
Sin, N., et al. 1999. Bioorg. Med. Chem. Lett. 9, 2283.
Hanada, M., et al. 1992. J. Antibiot. 45, 1746.
Legal Information
CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany
Disclaimer
Toxicity: Standard Handling (A)
Classe de stockage
11 - Combustible Solids
wgk
WGK 3
Certificats d'analyse (COA)
Recherchez un Certificats d'analyse (COA) en saisissant le numéro de lot du produit. Les numéros de lot figurent sur l'étiquette du produit après les mots "Lot" ou "Batch".
Déjà en possession de ce produit ?
Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.
Contenu apparenté
Diti Chatterjee Bhowmick et al.
The Journal of biological chemistry, 293(37), 14210-14223 (2018-07-18)
Human islet amyloid polypeptide (hIAPP) is the principal constituent of amyloid deposits and toxic oligomers in the pancreatic islets. Together with hyperglycemia, hIAPP-derived oligomers and aggregates are important culprits in type 2 diabetes mellitus (T2DM). Here, we explored the role
Jin Rui Liang et al.
Cell, 180(6), 1160-1177 (2020-03-12)
Selective autophagy of organelles is critical for cellular differentiation, homeostasis, and organismal health. Autophagy of the ER (ER-phagy) is implicated in human neuropathy but is poorly understood beyond a few autophagosomal receptors and remodelers. By using an ER-phagy reporter and